Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema for Weight Management and Long-term Maintenance in Obesity
NCT07011667Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of CagriSema in obesity, sponsored by Novo Nordisk. Started Jun 2025; status: active, not recruiting.
02
Drugs
CagriSema
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07011667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011667.